Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) disclosed a report regarding the reduction of shares by its controlling shareholder, Baiyang Group, which has triggered a change in shareholding that touches a 5% integer multiple threshold [1][2]. Summary by Sections Share Reduction Plan - Baiyang Group plans to reduce its shareholding by up to 15,768,585 shares, accounting for 3.00% of the total share capital, through centralized bidding and/or block trading from August 12, 2025, to November 11, 2025 [1]. - As of the report date, the reduction plan has not been fully executed [1]. Execution of Share Reduction - From August 12 to August 13, 2025, Baiyang Group reduced its shares by 10,512,390 shares, representing 2.00% of the total share capital through block trading [1]. - From September 11 to November 3, 2025, an additional 1,994,500 shares were reduced through centralized bidding, accounting for 0.38% of the total share capital, leading to a total reduction of 12,506,890 shares [1]. Financial Impact - The average share prices during the reduction period were 26.43 yuan and 28.05 yuan, resulting in a total cash-out amount of approximately 333,788,192.7 yuan [2]. Shareholding Structure - As of the report date, the combined shareholding of the information disclosure obligors decreased to 394,218,110 shares, representing 75.00% of the total share capital, down from 406,725,000 shares, which was 77.46% prior to the reduction [2][3]. - The reduction does not lead to a change in the controlling shareholder or actual controller of the company, nor does it significantly impact the governance structure or future operations of the company [3].
百洋医药控股股东近3个月减持1251万股 套现3.34亿元